中文 English

BRCAim® BRCA1/2 Detection Assay

Detection method

The next-generation sequencing (NGS) used in this assay, compared to PCR and Sanger sequencing methods, can simultaneously detect mutations in multiple genes or regions. More genetic information can be quickly obtained from limited amounts patient samples.

Test significance

Provides medication guidance for PARP inhibitor targeted drugs and platinum chemotherapy drugs treating ovarian cancer and breast cancer, as well as genetic risk and prognosis assessment for ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.

Product advantage

- Covers the full coding region of BRCA1/2 genes. 

- Average on-target sequencing depth ≥1,000X. 

- Applicable for both paraffin embedded tissue samples and blood samples. 

- Professional genetic counseling teams provide clinical and genetic counseling services.

Detection of genes

Tumor genes(2)

  • BRCA1
  • BRCA2

Applicable to cancer patients

Test procedure

*Product is for research use only.